Tocilizumab - CISMeF

Preferred Label : Tocilizumab;

NCIt synonyms : Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer; MRA;

NCIt related terms : IL-6 receptor monoclonal antibodies: tocilizumab;

NCIt definition : A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.;

UNII : I031V2H011;

CAS number : 375823-41-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 375823-41-9 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : RoActemra; Actemra;

Molecule name : R-1569;

ChEBI ID : CHEBI:64360;

Codes from synonyms : 501;

Details

Origin ID

C84217;

UMLS CUI

C1609165;

Currated CISMeF NLP mapping
- Tocilizumab [Substance BNPC]
- Tocilizumab (substance) [SNOMED CT concept]
- tocilizumab [MeSH concept]
- tocilizumab [MeSH Supplementary Concept]
- tocilizumab [International Nonproprietary Name]
See also inter- (CISMeF)
- Product containing tocilizumab (medicinal product) [SNOMED CT concept]
- Roactemra [MeSH concept]
- Tocilizumab therapy (procedure) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing tocilizumab (medicinal product) [SNOMED CT concept]
- Tocilizumab [Substance BNPC]
- Tocilizumab [LOINC component]
- Tocilizumab (substance) [SNOMED CT concept]
- tocilizumab [ATC Code]
- tocilizumab [International Nonproprietary Name]
- tocilizumab [MeSH Supplementary Concept]
- tocilizumab [MeSH concept]
Validated automatic mappings to BTNT
- tocilizumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- ACC/AHA COVID-19 Appendix Variables [NCIt concept]
- ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology [NCIt concept]
- Appendix 8: Pharmacological Therapy Terminology [NCIt concept]
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
- Therapies for COVID-19 Terminology [NCIt concept]
has_target
- Interleukin-6 Receptor Subunit Alpha [NCIt concept]
- Soluble Interleukin-6 Receptor Subunit Alpha [NCIt concept]
is_component_of_chemotherapy_regimen
- Tocilizumab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients